Drugs / OpRegen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02286089 | Apr 2015 → Dec 2021 overdue | dry age related macular degeneration | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05626114 | Mar 2023 → Mar 2031 expected | diffuse secondary choroid atrophy | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OpRegen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286089 ↗ |
| Modality | Cell therapy | “OpRegen® is a cell-based product composed of retinal pigment epithelial (RPE) cells, derived from human embryonic stem cells (hESC)” NCT02286089 ↗ |
| Route | Other | “Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.” NCT02286089 ↗ |